title: A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.
abstract: A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our data suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment.
authors.affiliation: 1] Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Surgery [2].
authors.forename: Lianhai
authors.initials: L
authors.lastname: Zhang
authors.forename: Jie
authors.initials: J
authors.lastname: Yang
authors.forename: Jie
authors.initials: J
authors.lastname: Cai
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Song
authors.forename: Jianyun
authors.initials: J
authors.lastname: Deng
authors.forename: Xuesong
authors.initials: X
authors.lastname: Huang
authors.forename: Dawei
authors.initials: D
authors.lastname: Chen
authors.forename: Mengmeng
authors.initials: M
authors.lastname: Yang
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Wery
authors.forename: Shuangxi
authors.initials: S
authors.lastname: Li
authors.forename: Aiwen
authors.initials: A
authors.lastname: Wu
authors.forename: Ziyu
authors.initials: Z
authors.lastname: Li
authors.forename: Zhongwu
authors.initials: Z
authors.lastname: Li
authors.forename: Yiqiang
authors.initials: Y
authors.lastname: Liu
authors.forename: Yiyou
authors.initials: Y
authors.lastname: Chen
authors.forename: Qixiang
authors.initials: Q
authors.lastname: Li
authors.forename: Jiafu
authors.initials: J
authors.lastname: Ji
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000068818:Cetuximab; D004195:Disease Models, Animal; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005784:Gene Amplification; D015870:Gene Expression; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D051379:Mice; D009154:Mutation; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000068818:Cetuximab